Curis (CRIS) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Curis (CRIS) Reports In-Line Q2 EPS

Curis Reports Second Quarter 2016 Financial Results

August 4, 2016 7:01 AM EDT

LEXINGTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial results for the second quarter ended June 30, 2016.

"We are pleased that dosing of patients has started in the Phase 1 trial of CA-170, the first oral, small molecule immune checkpoint inhibitor targeting PD-L1 and VISTA pathways from our collaboration with Aurigene, said Ali Fattaey, Ph.D., Curis's President and CEO. Additionally, the second immuno-oncology program in our... More